Oxygenta Pharmaceutical Ltd.
BSE: OXYGENTAPH
Prev Close
49.86
Open Price
49.87
Volume
1,936
Today Low / High
49.86 / 52.96
52 WK Low / High
46 / 133.5
Range
49 - 55
The stock is currently available for trading on the Bombay Stock Exchange (BSE). Its price is 52.05, reflecting a change of 2.19 (4.3923%). The expected target range on the BSE is 49 - 55. The stock is showing an upward trend on the BSE, making it an appealing option for investors looking for growth in their portfolio.
Oxygenta Pharmaceutical Ltd. Graph
Oxygenta Pharmaceutical Ltd. Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Oxygenta Pharmaceutical Ltd. T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 52.05, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 52.05 | 52.57 | 47.31 - 57.83 |
| 53.09 | 42.47 - 63.71 | ||
| 53.61 | 37.53 - 69.69 | ||
| Bearish Scenario | 52.05 | 51.53 | 46.38 - 56.68 |
| 51.01 | 40.81 - 61.21 | ||
| 50.49 | 35.34 - 65.64 |
Overview of Oxygenta Pharmaceutical Ltd.
ISIN
INE102E01018
Industry
Medical - Pharmaceuticals
Vol.Avg
15,953
Market Cap
1,849,175,000
Last Dividend
0
Official Website
IPO Date
2000-01-03
DCF Diff
N/A
DCF
0
Financial Ratios Every Investor Needs
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 109.30 Cr | 107.63 Cr | 1.67 Cr | 0.0153 | 0.00 Cr | 2.00 Cr | -11.73 Cr | -10.30 Cr | -2.81 | -7.12 Cr | -0.0942 |
| 2024-03-31 | 39.64 Cr | 49.62 Cr | -9.98 Cr | -0.2517 | 0.00 Cr | 2.14 Cr | -12.36 Cr | -3.48 Cr | -1.09 | -9.62 Cr | -0.0878 |
| 2023-03-31 | 30.99 Cr | 30.58 Cr | 0.41 Cr | 0.0133 | 0.00 Cr | 0.68 Cr | -9.16 Cr | -11.57 Cr | -8.15 | -7.83 Cr | -0.3734 |
| 2022-03-31 | 60.52 Cr | 56.57 Cr | 3.96 Cr | 0.0654 | 0.00 Cr | 1.51 Cr | -0.10 Cr | -0.61 Cr | -0.48 | 2.03 Cr | -0.0101 |
| 2021-03-31 | 52.03 Cr | 42.30 Cr | 9.73 Cr | 0.1870 | 0.00 Cr | 1.33 Cr | 2.66 Cr | 2.93 Cr | 2.87 | 6.12 Cr | 0.0563 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 0.00 Cr | 82.80 Cr | 108.44 Cr | -25.6405 Cr | 62.23 Cr | 62.23 Cr | 20.51 Cr | 37.06 Cr | 0.00 Cr | 0.00 Cr | 1.81 Cr | 85.8474 Cr |
| 2024-03-31 | 0.00 Cr | 63.19 Cr | 83.31 Cr | -20.1224 Cr | 57.23 Cr | 57.23 Cr | 13.72 Cr | 29.36 Cr | 0.66 Cr | 0.00 Cr | -0.05 Cr | 33.6951 Cr |
| 2023-03-31 | 0.02 Cr | 54.26 Cr | 100.46 Cr | -46.2000 Cr | 67.99 Cr | 67.98 Cr | 11.71 Cr | 27.91 Cr | 0.00 Cr | 0.00 Cr | 0.45 Cr | 29.8171 Cr |
| 2022-03-31 | 0.07 Cr | 31.18 Cr | 65.81 Cr | -34.6291 Cr | 52.13 Cr | 52.06 Cr | 7.28 Cr | 20.32 Cr | 0.00 Cr | 0.00 Cr | 0.84 Cr | 8.0411 Cr |
| 2021-03-31 | 0.37 Cr | 33.86 Cr | 71.88 Cr | -38.0186 Cr | 47.89 Cr | 47.52 Cr | 12.11 Cr | 16.97 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 18.8367 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 0.8437 Cr | -11.2716 Cr | 10.4487 Cr | -8.7887 Cr | 0.0209 Cr | 0.1217 Cr | -11.3915 Cr | -14.3514 Cr | 4.9988 Cr | 0.0000 Cr | -6.7965 Cr |
| 2024-03-31 | -13.0496 Cr | -4.0878 Cr | 17.1320 Cr | -18.7315 Cr | -0.0054 Cr | 0.1008 Cr | -4.1056 Cr | -3.4793 Cr | -10.7598 Cr | 0.0000 Cr | -2.0114 Cr |
| 2023-03-31 | -1.6337 Cr | -9.6399 Cr | 11.2241 Cr | -12.7611 Cr | -0.0495 Cr | 0.1062 Cr | -9.6450 Cr | -11.5710 Cr | 12.7117 Cr | 0.0000 Cr | -4.4220 Cr |
| 2022-03-31 | -1.6799 Cr | -4.9411 Cr | 6.3317 Cr | -7.5460 Cr | -0.2893 Cr | 0.1557 Cr | -4.9456 Cr | -0.6105 Cr | 3.2566 Cr | 0.0000 Cr | 4.8306 Cr |
| 2021-03-31 | -1.6219 Cr | -6.7187 Cr | 8.6673 Cr | -8.3632 Cr | 0.3267 Cr | 0.4450 Cr | -6.7412 Cr | 3.1438 Cr | 10.4502 Cr | 0.0000 Cr | -7.8606 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | 33.93 Cr | 38.06 Cr | -4.13 Cr | -0.1217 | -4.94 Cr | -4.84 Cr | -1.31 | -4.08 Cr | -0.1427 |
| 2025-09-30 | 14.25 Cr | 19.12 Cr | -4.88 Cr | -0.3423 | -5.49 Cr | -4.93 Cr | -1.33 | -4.63 Cr | -0.3461 |
| 2025-06-30 | 15.13 Cr | 18.82 Cr | -3.68 Cr | -0.2433 | -7.68 Cr | -6.11 Cr | -1.65 | -6.67 Cr | -0.4035 |
| 2025-03-31 | 49.47 Cr | 47.23 Cr | 2.24 Cr | 0.0452 | -1.40 Cr | -2.15 Cr | -0.59 | -1.90 Cr | -0.0435 |
| 2024-12-31 | 33.21 Cr | 35.05 Cr | -1.85 Cr | -0.0556 | -5.06 Cr | -3.93 Cr | -1.07 | -3.87 Cr | -0.1183 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 1.24 Cr | 0.10 Cr | 1.24 Cr | 15.73 Cr | 27.09 Cr | 51.92 Cr | 41.55 Cr | 116.77 Cr | 153.44 Cr |
| 2025-03-31 | 0.00 Cr | 0.12 Cr | 0.12 Cr | 5.10 Cr | 20.51 Cr | 30.94 Cr | 37.06 Cr | 82.80 Cr | 108.44 Cr |
| 2024-09-30 | 0.00 Cr | 0.10 Cr | 0.10 Cr | 15.16 Cr | 14.09 Cr | 32.33 Cr | 29.82 Cr | 73.25 Cr | 94.39 Cr |
| 2024-03-31 | 0.00 Cr | 0.10 Cr | 0.10 Cr | 7.37 Cr | 14.13 Cr | 24.11 Cr | 29.36 Cr | 63.19 Cr | 83.31 Cr |
| 2023-09-30 | 0.01 Cr | 0.08 Cr | 0.09 Cr | 16.27 Cr | 12.70 Cr | 32.30 Cr | 29.75 Cr | 64.16 Cr | 88.60 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2023-12-31 | -3.36 Cr | 1.38 Cr | 0.00 Cr | 0.00 Cr | 1.38 Cr | 1.38 Cr | 0.01 Cr | 0.00 Cr | 1.38 Cr |
| 2023-09-30 | -3.16 Cr | -3.16 Cr | 0.00 Cr | 0.00 Cr | -3.16 Cr | 0.01 Cr | 3.17 Cr | 0.00 Cr | -3.16 Cr |
| 2023-06-30 | -4.56 Cr | -4.56 Cr | 0.00 Cr | 0.00 Cr | -4.67 Cr | -4.56 Cr | 0.11 Cr | 0.00 Cr | -4.56 Cr |
| 2023-03-31 | -4.29 Cr | -4.29 Cr | 0.00 Cr | 0.00 Cr | -4.29 Cr | 0.11 Cr | 4.40 Cr | 0.00 Cr | -4.29 Cr |
| 2022-12-31 | -3.25 Cr | -3.25 Cr | 0.00 Cr | 0.00 Cr | -3.25 Cr | -3.25 Cr | 0.00 Cr | 0.00 Cr | -3.25 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| No split history data available. | ||
Similar Stocks: Medical - Pharmaceuticals
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| MedPlus Health Services Limited | MEDPLUS | ₹830.35 | ₹99,644,807,413.00 | ₹76,499.00 |
Key Executives
Gender: male
Year Born: 1964
Gender: male
Year Born: 1962
Gender: female
Year Born:
Gender: Not Specified
Year Born:
Gender: Not Specified
Year Born:
Gender: male
Year Born:
Gender: Not Specified
Year Born:
FAQs about Oxygenta Pharmaceutical Ltd.
The CEO is Prasad Reddy Battinapatla.
The current price is ₹50.00.
The range is ₹46.6-133.5.
The market capitalization is ₹184.92 crores.
The P/E ratio is -10.25.
The company operates in the Healthcare sector.
Overview of Oxygenta Pharmaceutical Ltd. (ISIN: INE102E01018) is a leading Medical - Pharmaceuticals in India. With a market capitalization of ₹184.92 crores and an average daily volume of 15,953 shares, it operates in the Medical - Pharmaceuticals. The company last declared a dividend of ₹0.